silke gillessen(@Silke_Gillessen) 's Twitter Profileg
silke gillessen

@Silke_Gillessen

Medical Oncologist, Oncology Institute of Southern Switzerland, views are mine

ID:2173819306

calendar_today08-11-2013 22:14:33

896 Tweets

2,3K Followers

1,1K Following

Follow People
silke gillessen(@Silke_Gillessen) 's Twitter Profile Photo

Very well deserved! Tom Powles has done so much for the field of oncology also before this great success and surely he will do even more in the future! An amazing oncologist!

account_circle
Barts Cancer Institute (Queen Mary)(@QMBCI) 's Twitter Profile Photo

🎉Congratulations to BCI's Prof Tom Powles who has been recognised by TIME Magazine in their inaugural list of 100 individuals who most influenced global health this year for his breakthrough success in treating severe .

📰 time.com/6967129/thomas…

🎉Congratulations to BCI's Prof @tompowles1 who has been recognised by @TIME Magazine in their inaugural #TIME100HEALTH list of 100 individuals who most influenced global health this year for his breakthrough success in treating severe #bladdercancer. 📰 time.com/6967129/thomas…
account_circle
Giulia Marvaso(@GiuliaMarvaso84) 's Twitter Profile Photo

It's The Lancet Oncology day for Rad Onc GU! Our consensus on SBRT for Oligomets RCC is finally out! Thanks to all the participants! 🔥🔥🔥🌟🌟🌟
Delphi consensus on stereotactic ablative radiotherapy for oligometast... sciencedirect.com/science/articl…

It's @TheLancetOncol day for Rad Onc GU! Our consensus on SBRT for Oligomets RCC is finally out! Thanks to all the participants! 🔥🔥🔥🌟🌟🌟 Delphi consensus on stereotactic ablative radiotherapy for oligometast... sciencedirect.com/science/articl…
account_circle
Juan Antonio Vallejo #SinCienciaNoHayFuturo(@DrJaVallejo) 's Twitter Profile Photo

GREAT IDEA!!! A necessary forum to unify concepts in the use of diagnostic tools in Prostate cancer. PSMA PET/CT will be the winner, but it will help better define its usefulness. APCCC DIAGNOSTIC 2025. prof. Stefano Fanti Ken Herrmann Michael Hofman Advanced Prostate Cancer Consensus Conference Declan Murphy

account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus!

Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus! #APCCC24 @APCCC_Lugano @Silke_Gillessen @AOmlin…
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

A significant 80% of respondents report that genetic evaluation (germline and/or somatic) does influence their decision-making for the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) when testing is available without restrictions outside of a…

A significant 80% of respondents report that genetic evaluation (germline and/or somatic) does influence their decision-making for the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) when testing is available without restrictions outside of a…
account_circle
Daniel Castellano(@cdanicas) 's Twitter Profile Photo

APCCC 2024: Dealing with Inequality – What Can We Learn from the Brazilian Unified Healthcare System (SUS): Opportunities for Big Data Mining and System Remodeling urotoday.com/conference-hig…

account_circle
Uromigos(@Uromigos) 's Twitter Profile Photo

APCCC debate with Thomas Zilli and Pierre Blanchard covering radiation therapy for metastatic disease from Lugano. Thanks to Neeraj Agarwal, MD, FASCO for help with the tweet. OncoAlert . t.ly/D7N0_

account_circle